לוג'וקסטה 10 מג ישראל - עברית - Ministry of Health

לוג'וקסטה 10 מג

medison pharma ltd - lomitapide as mesylate - קפסולות - lomitapide as mesylate 10 mg - lomitapide

לוג'וקסטה 20 מג ישראל - עברית - Ministry of Health

לוג'וקסטה 20 מג

medison pharma ltd - lomitapide as mesylate - קפסולות - lomitapide as mesylate 20 mg - lomitapide

לוג'וקסטה 5 מג ישראל - עברית - Ministry of Health

לוג'וקסטה 5 מג

medison pharma ltd - lomitapide as mesylate - קפסולות - lomitapide as mesylate 5 mg - lomitapide

קרם מרוכז עץ התה ישראל - עברית - Ministry of Health

קרם מרוכז עץ התה

אן.אס.פי. בעמ - שיפור מראה העור

זולג'נסמה ישראל - עברית - Ministry of Health

זולג'נסמה

novartis israel ltd - onasemnogene abeparvovec - תרחיף - onasemnogene abeparvovec 2 x 10^13 vg / 1 ml - onasemnogene abeparvovec

אפיניטור 5 מג ישראל - עברית - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 10 מג ישראל - עברית - Ministry of Health

אפיניטור 10 מג

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 2.5 מג ישראל - עברית - Ministry of Health

אפיניטור 2.5 מג

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

פיקריי 150 מג ישראל - עברית - Ministry of Health

פיקריי 150 מג

novartis israel ltd - alpelisib - טבליות מצופות פילם - alpelisib 150 mg - alpelisib

פיקריי 200 מג ישראל - עברית - Ministry of Health

פיקריי 200 מג

novartis israel ltd - alpelisib - טבליות מצופות פילם - alpelisib 200 mg - alpelisib